Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) started the day on March 26, 2021, with a price increase of 1.07% at $214.64. During the day, the stock rose to $214.96 and sunk to $209.22 before settling in for the price of $212.36 at the close. Taking a more long-term approach, VRTX posted a 52-week range of $202.57-$306.08.
In the past 5-years timespan, the Healthcare sector firm’s annual sales growth was 43.20%. Meanwhile, its Annual Earning per share during the time was 45.30%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 128.00%. This publicly-traded company’s shares outstanding now amounts to $259.96 million, simultaneously with a float of $259.37 million. The organization now has a market capitalization sitting at $55.21 billion. At the time of writing, stock’s 50-day Moving Average stood at $218.16, while the 200-day Moving Average is $245.29.
If we measure the efficiency of the company that is accounted for 3400 employees. It has generated 1,826,293 per worker during the last fiscal year. Meanwhile, its income per employee was 797,543. The stock had 8.18 Receivables turnover and 0.62 Total Asset turnover. For the Profitability, stocks gross margin was +88.14, operating margin was +46.27 and Pretax Margin of +50.19.
Vertex Pharmaceuticals Incorporated (VRTX) Ownership Facts and Figures
Now let’s turn our focus to how large-scale investors are working with this stock of the Biotechnology Industry. Vertex Pharmaceuticals Incorporated’s current insider ownership accounts for 0.20%, in contrast to 94.30% institutional ownership. According to the most recent insider trade that took place on Mar 05, this organization’s SVP, General Counsel sold 5,141 shares at the rate of 209.69, making the entire transaction reach 1,078,018 in total value, affecting insider ownership by 8,253. Preceding that transaction, on Mar 01, Company’s SVP & Chief Accounting Officer sold 2,782 for 211.45, making the whole transaction’s value amount to 588,255. This particular insider is now the holder of 9,884 in total.
Vertex Pharmaceuticals Incorporated (VRTX) Earnings and Revenue Records
In the latest quarterly report released, which was put into the public domain on 12/30/2020, the organization reported $2.51 earnings per share (EPS) for the three months, lower than the consensus estimate (set at $2.59) by -$0.08. This company achieved a net margin of +43.67 while generating a return on equity of 36.71. Wall Street market experts anticipate that the next fiscal year will bring earnings of 2.78 per share during the current fiscal year.
Vertex Pharmaceuticals Incorporated’s EPS increase for this current 12-month fiscal period is 128.00% and is forecasted to reach 13.08 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 18.33% through the next 5 years, which can be compared against the 45.30% growth it accomplished over the previous five years trading on the market.
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) Trading Performance Indicators
Let’s observe the current performance indicators for Vertex Pharmaceuticals Incorporated (VRTX). It’s Quick Ratio in the last reported quarter now stands at 4.20. The Stock has managed to achieve an average true range (ATR) of 5.45. Alongside those numbers, its PE Ratio stands at $20.83, and its Beta score is 0.68. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 8.90. Similarly, its price to free cash flow for trailing twelve months is now 18.44.
In the same vein, VRTX’s Diluted EPS (Earnings per Share) trailing twelve months is recorded 10.30, a figure that is expected to reach 2.71 in the next quarter, and analysts are predicting that it will be 13.08 at the market close of one year from today.
Technical Analysis of Vertex Pharmaceuticals Incorporated (VRTX)
If we take a close look at the recent performances of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), its last 5-days Average volume was 2.04 million that shows plunge from its year to date volume of 2.12 million. During the previous 9 days, stock’s Stochastic %D was recorded 30.92% While, its Average True Range was 5.26.
Raw Stochastic average of Vertex Pharmaceuticals Incorporated (VRTX) in the period of the previous 100 days is set at 29.87%, which indicates a major fall in contrast to 47.49% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 19.66% that was lower than 26.98% volatility it exhibited in the past 100-days period.